PUBLIC COMPANY
saveVerona Pharma Ltd
updated 12d ago
community read0 votes
pipeline
2
marketed
1
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Phase 21Marketed
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD
- phase2Effect of Ensifentrine on Sputum Markers of Inflammation in COPD
- phase2A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD
- phase2A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease
- phase2A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis
- phase3Effect of Ensifentrine Treatment on CAT Score
- phase2A Study of RPL554 in Patients With Cystic Fibrosis
- phase3A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
🐶 Hiring Signal
News
- A COPD drug from China draws $115M in venture fundingExpedition Therapeutics, which has raised nearly $300 million to date, is studying a drug it believes to have notable advantages over other COPD treatments either in development or on the market.biopharma_dive · 6d ago
- Merck’s $10.8B Prometheus deal delivers another win—plus a Phase 2b missThe anti-TL1A antibody from Merck's 2023 Prometheus buy delivered positive mid-stage results in a skin condition but failed in a certain type of lung disease, the Big Pharma revealed alongside seco…biospace · 7d ago
- AstraZeneca, GSK intensify China ties with Sino Biopharm dealsThe U.K. drugmakers added to a series of recent tie-ups with Chinese counterparts amid broader scrutiny of such transactions in the U.S.biopharma_dive · 1mo ago
- Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.Young biotechs usually get acquired instead of profitably selling their own medicines. A growing number are proving they can, which could make the sector more broadly appealing to investors, some say.biopharma_dive · 3mo ago
comments(0)
5-min edit window · permanent after that